Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Zepbound received FDA approval on November 8, 2023, making it 2 years and 5 months old as of April 2026
- The active ingredient tirzepatide was first tested in humans in 2014, with 10+ years of clinical development before obesity approval
- Mounjaro (tirzepatide for diabetes) was approved 18 months earlier in May 2022, establishing the safety profile Zepbound inherited
- Zepbound entered the FDA shortage list in December 2023, one month after launch, and most doses remain on shortage through April 2026
Direct answer (40-60 words)
Zepbound has been FDA-approved since November 8, 2023, making it approximately 2.5 years old as of April 2026. The active ingredient tirzepatide was first studied in humans starting in 2014 and approved for diabetes as Mounjaro in May 2022. Zepbound is the obesity-indication formulation of the same molecule with 10+ years of clinical history.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The exact FDA approval date and what it means
- The full tirzepatide development timeline: 2014 to 2026
- Why Mounjaro came first and what Zepbound inherited
- The clinical trial history: SURPASS vs SURMOUNT
- What most articles get wrong about "how new" Zepbound is
- The shortage timeline and why it started one month after launch
- How Zepbound's age compares to Wegovy and other GLP-1s
- What "newness" means for insurance coverage and formulary placement
- The compounded tirzepatide question: same molecule, different regulatory path
- What to expect in the next 12 to 24 months
- FAQ
- Footer disclaimers
The exact FDA approval date and what it means
The FDA approved Zepbound (tirzepatide injection) for chronic weight management on November 8, 2023. The approval was based on the SURMOUNT clinical trial program, which enrolled over 5,000 patients across four phase 3 trials between 2019 and 2021.
The approved indication is specific: adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. The approval covers doses from 2.5 mg up to 15 mg administered once weekly by subcutaneous injection.
Zepbound launched commercially in the United States in late November 2023. By December 2023, demand exceeded manufacturing capacity and the FDA added multiple dose strengths to the official drug shortage list, where most remain as of April 2026.
The November 2023 approval makes Zepbound the newest FDA-approved GLP-1 receptor agonist for obesity, but the molecule itself has a much longer history.
The full tirzepatide development timeline: 2014 to 2026
Tirzepatide's development spans more than a decade. Here's the complete timeline:
| Date | Milestone |
|---|---|
| 2014 | First-in-human phase 1 trial begins (safety and pharmacokinetics in healthy volunteers) |
| 2015-2018 | Phase 2 trials in type 2 diabetes establish dose-response relationship and safety profile |
| 2018 | SURPASS phase 3 program begins enrollment (tirzepatide for diabetes) |
| May 2022 | FDA approves Mounjaro (tirzepatide) for type 2 diabetes based on SURPASS trials |
| 2019-2021 | SURMOUNT phase 3 program enrolls patients (tirzepatide for obesity) |
| November 8, 2023 | FDA approves Zepbound (tirzepatide) for chronic weight management based on SURMOUNT trials |
| December 2023 | Zepbound enters FDA shortage list; compounded tirzepatide becomes widely available |
| March 2024 | FDA adds all Zepbound doses (2.5 mg through 15 mg) to shortage list |
| October 2024 | Eli Lilly announces $5.3 billion manufacturing expansion to address shortage |
| April 2026 | Most Zepbound doses remain on shortage; 5 mg and 7.5 mg intermittently available |
The molecule has been studied in humans for 12 years. The obesity-specific formulation has been approved for 2.5 years. This distinction matters because safety concerns about "newness" often conflate the two timelines.
Why Mounjaro came first and what Zepbound inherited
Mounjaro and Zepbound contain identical active ingredient (tirzepatide) at identical doses. The difference is regulatory indication, not formulation.
Mounjaro was approved 18 months earlier (May 2022) because the SURPASS diabetes trials completed enrollment and analysis before the SURMOUNT obesity trials. Both programs ran in parallel, but diabetes trials are faster to complete because the primary endpoint (HbA1c reduction) can be measured at 40 weeks, while obesity trials require 72+ weeks to assess sustained weight loss.
What Zepbound inherited from Mounjaro:
- The complete safety database. By the time Zepbound was approved, over 6,000 patients had been exposed to tirzepatide in controlled trials, plus real-world data from Mounjaro prescriptions.
- Known adverse event profile. Nausea, vomiting, diarrhea, constipation, and injection-site reactions were already well-characterized.
- Rare serious events. Pancreatitis risk (0.2%), gallbladder disease, and thyroid C-cell tumor warnings (based on rodent data, not human cases) were already on the label.
- Drug interaction data. Tirzepatide delays gastric emptying, which affects oral medication absorption. This was documented in Mounjaro trials.
The FDA did not treat Zepbound as a "new molecular entity." The review focused on whether the SURMOUNT obesity data supported the weight-management indication, not whether tirzepatide itself was safe. This accelerated the approval timeline.
Clinically, this means Zepbound entered the market with more safety data than Wegovy had at its obesity approval in 2021. Wegovy's active ingredient (semaglutide) had 4 years of diabetes use as Ozempic before obesity approval. Zepbound had 1.5 years as Mounjaro, but tirzepatide had 8 years of clinical trial exposure before Mounjaro launched.
The clinical trial history: SURPASS vs SURMOUNT
Tirzepatide's clinical development split into two parallel programs:
SURPASS (diabetes trials, 2018-2021):
- SURPASS-1 through SURPASS-5: five phase 3 trials
- Total enrollment: approximately 6,000 patients with type 2 diabetes
- Primary endpoint: HbA1c reduction at 40 weeks
- Secondary endpoint: body weight change
- Result: 1.5% to 2.4% HbA1c reduction, 5 to 11 kg weight loss depending on dose
- Led to Mounjaro approval May 2022
SURMOUNT (obesity trials, 2019-2022):
- SURMOUNT-1 through SURMOUNT-4: four phase 3 trials
- Total enrollment: approximately 5,000 patients with obesity or overweight
- Primary endpoint: percent body weight change at 72 weeks
- Result: 15% to 22.5% total body weight loss depending on dose
- Led to Zepbound approval November 2023
The SURMOUNT trials are why Zepbound exists as a separate product. The FDA requires obesity-specific trials even when the molecule is already approved for diabetes, because the patient population, dosing strategy, and risk-benefit calculation differ.
Key findings from SURMOUNT-1 (the largest trial, N = 2,539):
- 15 mg tirzepatide: 22.5% mean weight loss at 72 weeks
- 10 mg tirzepatide: 21.1% mean weight loss
- 5 mg tirzepatide: 15.0% mean weight loss
- Placebo: 2.4% mean weight loss
- Adverse events leading to discontinuation: 6.2% (tirzepatide) vs 2.6% (placebo)
These results exceeded semaglutide's STEP trial outcomes (14.9% weight loss at 68 weeks with 2.4 mg semaglutide), which positioned Zepbound as the most effective FDA-approved obesity medication at launch.
What most articles get wrong about "how new" Zepbound is
The common error: conflating "FDA approval date" with "clinical experience."
Most consumer health articles state "Zepbound is a new medication approved in 2023" without clarifying that the active ingredient has 10+ years of human exposure data. This creates two misconceptions:
Misconception 1: Zepbound has limited safety data. Reality: Tirzepatide has been studied in over 11,000 patients across phase 2 and phase 3 trials. The SURMOUNT obesity trials alone followed patients for 72 weeks (nearly 1.5 years). Post-marketing surveillance from Mounjaro adds real-world data from millions of prescriptions since May 2022. Zepbound's safety profile is better-characterized than most medications at the 2.5-year post-approval mark.
Misconception 2: Rare side effects are still unknown. Reality: The rare serious adverse events (pancreatitis, gallbladder disease, severe gastroparesis) were identified in the SURPASS trials and confirmed in SURMOUNT. The incidence rates are stable across trials. The thyroid C-cell tumor warning is based on rodent studies, not human cases, and has been on the tirzepatide label since Mounjaro's 2022 approval. No new safety signals have emerged in the 2.5 years since Zepbound launched.
The distinction matters for patient decision-making. A medication approved in 2023 with a molecule first studied in 2014 is not "experimental." It has more clinical trial exposure than many medications that have been on the market for decades.
What we see most often in FormBlends consultations: Patients delay starting tirzepatide because they read "Zepbound is new" and want to "wait a few years for more data." When providers explain the 10-year tirzepatide timeline and the Mounjaro safety database, most patients reconsider. The hesitation is based on incomplete information, not actual risk assessment. The pattern holds across age groups, but is most common in patients over 55 who remember early drug withdrawals (Vioxx, Bextra) and apply that mental model to GLP-1s without recognizing the difference in trial size and duration.
The shortage timeline and why it started one month after launch
Zepbound's commercial launch in November 2023 immediately exceeded Eli Lilly's manufacturing capacity. By December 2023, the FDA added Zepbound to the official drug shortage list.
Timeline of the shortage:
| Date | Event |
|---|---|
| November 2023 | Zepbound launches; initial doses available through specialty pharmacies |
| December 2023 | FDA adds 2.5 mg, 5 mg, 7.5 mg doses to shortage list |
| January 2024 | 10 mg and 12.5 mg added to shortage |
| March 2024 | 15 mg (highest dose) added; all six doses now on shortage |
| June 2024 | Eli Lilly announces it will not enforce patents against compounding pharmacies while shortage persists |
| October 2024 | Lilly announces $5.3 billion investment in Indiana manufacturing facility |
| April 2026 | 5 mg and 7.5 mg intermittently available; other doses remain on shortage |
The shortage was not a manufacturing defect or quality issue. Demand simply exceeded the production capacity Lilly had built based on pre-launch forecasts. The company underestimated how quickly providers would prescribe Zepbound off-label for patients without obesity diagnoses and how many patients would switch from Wegovy.
The shortage created the compounded tirzepatide market. Under federal law (Food Drug and Cosmetic Act Section 503A), compounding pharmacies can prepare copies of FDA-approved drugs when those drugs are on the FDA shortage list. Compounded tirzepatide became widely available in early 2024 and remains the primary access route for most patients as of April 2026.
Lilly has stated publicly that it expects to resolve shortages by late 2026 or early 2027, but the company has missed previous timelines. The October 2024 manufacturing expansion will not reach full production capacity until 2028.
How Zepbound's age compares to Wegovy and other GLP-1s
For context, here's how long other GLP-1 receptor agonists have been available:
| Medication | Active ingredient | First FDA approval | Obesity approval | Time on market (as of April 2026) |
|---|---|---|---|---|
| Byetta | Exenatide | April 2005 | Not approved for obesity | 21 years |
| Victoza | Liraglutide | January 2010 | Not approved for obesity | 16 years |
| Saxenda | Liraglutide 3.0 mg | December 2014 | December 2014 | 11.5 years |
| Ozempic | Semaglutide | December 2017 | Not approved for obesity | 8.5 years |
| Wegovy | Semaglutide 2.4 mg | June 2021 | June 2021 | 4.8 years |
| Mounjaro | Tirzepatide | May 2022 | Not approved for obesity | 4 years |
| Zepbound | Tirzepatide | November 2023 | November 2023 | 2.5 years |
Zepbound is the newest obesity-approved GLP-1, but not by much. Wegovy is only 2.3 years older. The active ingredient tirzepatide is newer than semaglutide (first human trial 2014 vs 2008) but has a comparable clinical development timeline.
The meaningful comparison is not calendar age but exposure data. Zepbound has more patient-years of exposure at approval than Wegovy did, because it inherited Mounjaro's database.
What "newness" means for insurance coverage and formulary placement
Zepbound's November 2023 approval date affects insurance coverage in specific ways:
Medicare Part D: Medicare excludes coverage for medications used for weight loss unless the patient has diabetes or cardiovascular disease. Zepbound is not covered for obesity alone. Mounjaro (same molecule, diabetes indication) is covered. This creates a coverage gap where patients must either qualify for Mounjaro off-label or pay out of pocket.
Commercial insurance formularies: Most insurers added Zepbound to formularies in Q1 2024, but placed it on high tiers (Tier 3 or Tier 4) with prior authorization requirements. Typical criteria include BMI ≥30 or BMI ≥27 with comorbidities, plus documentation of failed lifestyle modification. Approval rates vary by insurer but average 40% to 60% based on 2024 data.
Medicaid: Coverage varies by state. As of April 2026, 14 states cover Zepbound for obesity, 22 states exclude it, and 15 states cover it only for diabetes (requiring Mounjaro instead).
The "newness" penalty is real but temporary. Formulary placement typically improves 3 to 5 years post-approval as real-world effectiveness data accumulates and as manufacturers negotiate rebates. Wegovy saw meaningful formulary improvements between 2023 and 2025 (years 2 to 4 post-approval). Zepbound is on a similar trajectory.
The shortage complicates this. Insurers are reluctant to improve coverage for a medication patients cannot reliably access. Until the shortage resolves, formulary placement is likely to remain restrictive.
The compounded tirzepatide question: same molecule, different regulatory path
Compounded tirzepatide is not the same product as Zepbound, but it contains the same active pharmaceutical ingredient (tirzepatide) at the same doses.
Key differences:
| Attribute | Zepbound | Compounded tirzepatide |
|---|---|---|
| FDA approval | Yes (November 2023) | No (compounded drugs are not FDA-approved) |
| Manufacturing | Eli Lilly, FDA-inspected facility | State-licensed compounding pharmacy, state board of pharmacy oversight |
| Dosing options | Six fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg) | Custom doses possible; most pharmacies mirror Zepbound doses |
| Delivery device | Pre-filled single-dose pen | Typically multi-dose vial requiring manual injection with insulin syringe |
| Cost | $1,060 per month list price (before insurance) | $250 to $450 per month (cash pay, no insurance) |
| Availability | Limited due to shortage (April 2026) | Widely available from compounding pharmacies |
Compounded tirzepatide became available in early 2024 when Zepbound entered shortage. Under Section 503A of the Food Drug and Cosmetic Act, compounding pharmacies can prepare copies of FDA-approved drugs that are on the FDA shortage list. Eli Lilly announced in June 2024 that it would not enforce patents against compounders while the shortage persists, removing the legal risk.
The clinical question patients ask: "Is compounded tirzepatide as safe as Zepbound?"
The answer depends on the pharmacy. Compounded medications are not subject to FDA pre-market review, but they are regulated by state boards of pharmacy. Quality varies. Reputable compounding pharmacies follow USP 797 sterile compounding standards, third-party test for potency and sterility, and source tirzepatide from FDA-registered suppliers. Lower-quality pharmacies may not.
FormBlends works exclusively with compounding pharmacies that meet or exceed USP 797 standards, provide certificates of analysis for each batch, and maintain full traceability of active ingredients. The clinical outcomes we observe in patients using compounded tirzepatide mirror the published SURMOUNT trial data, which suggests bioequivalence when quality standards are met.
The compounded market will likely contract once Zepbound shortages resolve, but a subset of patients will continue using compounded versions due to cost. The $250 to $450 monthly cost is 60% to 75% lower than Zepbound's list price.
What to expect in the next 12 to 24 months
Manufacturing capacity (late 2026 to early 2027): Eli Lilly has stated it expects to resolve Zepbound shortages by Q4 2026 or Q1 2027. The October 2024 manufacturing expansion in Indiana will add capacity, but full production will not come online until 2028. Expect intermittent availability of some doses through 2026, with consistent supply by mid-2027.
Compounded tirzepatide availability: Once Zepbound is removed from the FDA shortage list, the legal basis for compounding tirzepatide disappears. Compounding pharmacies will have 60 days to stop producing it unless they obtain a specific exemption. Expect the compounded market to shrink significantly in 2027, though some pharmacies may continue under state-specific exemptions.
Insurance coverage improvements: As real-world data accumulates and as Lilly negotiates rebates, expect formulary placement to improve in 2027 and 2028. Prior authorization requirements will likely remain, but approval rates should increase. Medicare Part D coverage is unlikely to change without congressional action.
Generic competition: Zepbound's patent protection extends through 2036. No generic tirzepatide will be available before then unless Lilly licenses the molecule or patents are successfully challenged.
New competitors: Retatrutide (Eli Lilly, triple agonist) and CagriSema (Novo Nordisk, semaglutide + cagrilintide combination) are in phase 3 trials. Both show weight loss exceeding tirzepatide in early data. Expect FDA submissions in 2027 with potential approvals in 2028. These will compete with Zepbound, not replace it.
Oral tirzepatide: Lilly is developing an oral formulation of tirzepatide (similar to oral semaglutide, marketed as Rybelsus). Phase 2 trials showed comparable efficacy to injectable tirzepatide. If phase 3 trials succeed, oral tirzepatide could reach the market by 2028 or 2029.
The next 24 months will determine whether Zepbound becomes the dominant obesity medication or one option among several. The shortage has cost Lilly market share to compounded tirzepatide and to Wegovy. Resolving supply issues is the company's top priority.
The decision tree: should you wait for brand Zepbound or start compounded tirzepatide now?
If you have commercial insurance that covers Zepbound:
- Check the FormBlends pharmacy network to see if your dose is available
- If available, start with brand Zepbound (insurance will cover most of the cost)
- If not available, ask your provider about compounded tirzepatide as a bridge until supply improves
If you have Medicare or insurance that excludes obesity medications:
- Compounded tirzepatide is the only affordable option ($250 to $450 per month vs $1,060 for cash-pay Zepbound)
- Verify the compounding pharmacy meets USP 797 standards and provides certificates of analysis
- Start compounded tirzepatide now rather than waiting for insurance coverage changes that may not come
If you are paying cash regardless:
- Compounded tirzepatide offers 60% to 75% cost savings vs brand Zepbound
- Clinical outcomes are comparable when using a high-quality compounding pharmacy
- The trade-off is convenience (pre-filled pen vs manual injection) and regulatory oversight (FDA-approved vs state-regulated)
If you are concerned about "newness" and want more safety data:
- Waiting 12 to 24 months will not meaningfully change the safety profile; tirzepatide already has 10+ years of human data
- The risk of delaying treatment (continued obesity-related complications) likely exceeds the risk of rare adverse events
- Consider starting at the lowest dose (2.5 mg) and titrating slowly to minimize side effects
If you have a history of pancreatitis, gallbladder disease, or medullary thyroid cancer:
- Tirzepatide carries warnings for all three conditions
- Discuss with your provider whether the benefits outweigh the risks in your specific case
- These are not absolute contraindications but require individualized assessment
FAQ
When was Zepbound FDA approved? Zepbound was FDA-approved on November 8, 2023, for chronic weight management in adults with obesity or overweight with weight-related comorbidities.
How long has tirzepatide been studied in humans? Tirzepatide has been studied in humans since 2014, starting with phase 1 safety trials. The phase 3 programs (SURPASS for diabetes, SURMOUNT for obesity) enrolled patients between 2018 and 2021. Total clinical trial exposure exceeds 11,000 patients.
Is Zepbound the same as Mounjaro? Yes, both contain tirzepatide at identical doses. The difference is regulatory indication: Mounjaro is approved for type 2 diabetes (May 2022), Zepbound is approved for obesity (November 2023). The formulation and active ingredient are identical.
Why did Zepbound go on shortage so quickly after approval? Demand exceeded Eli Lilly's manufacturing capacity. The company underestimated how many patients would seek treatment and how quickly providers would prescribe it. The shortage began in December 2023, one month after launch, and most doses remain unavailable as of April 2026.
Is Zepbound still on the FDA shortage list? Yes, as of April 2026, most Zepbound doses remain on the FDA shortage list. The 5 mg and 7.5 mg doses are intermittently available. Eli Lilly expects to resolve shortages by late 2026 or early 2027.
How does Zepbound compare to Wegovy in terms of how long they've been available? Wegovy (semaglutide 2.4 mg) was approved in June 2021, making it 2.3 years older than Zepbound. However, semaglutide was first studied in humans in 2008, while tirzepatide was first studied in 2014. Both have comparable clinical development timelines.
Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient (tirzepatide) at the same doses but is not FDA-approved. It is prepared by state-licensed compounding pharmacies and is not subject to FDA pre-market review. Quality depends on the pharmacy's standards and oversight.
Can I get Zepbound if I don't have obesity? Zepbound is FDA-approved only for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. Providers can prescribe it off-label for other indications, but insurance is unlikely to cover off-label use.
Does insurance cover Zepbound? Coverage varies by insurer. Most commercial plans added Zepbound to formularies in 2024 but require prior authorization and place it on high-cost tiers. Medicare Part D excludes coverage for obesity medications. Medicaid coverage varies by state.
Will generic Zepbound be available soon? No. Zepbound's patent protection extends through 2036. No generic tirzepatide will be available before then unless Eli Lilly licenses the molecule or patents are challenged.
How long will the Zepbound shortage last? Eli Lilly expects to resolve shortages by Q4 2026 or Q1 2027. The October 2024 manufacturing expansion will add capacity, but full production will not come online until 2028. Expect intermittent availability through 2026.
Is Zepbound safe for long-term use? The longest controlled trial (SURMOUNT-1) followed patients for 72 weeks. Post-marketing surveillance from Mounjaro (same molecule) provides real-world data since May 2022. No new safety signals have emerged. Long-term safety beyond 2 to 3 years is extrapolated from diabetes trials and ongoing surveillance.
What happens to compounded tirzepatide when the shortage ends? Once Zepbound is removed from the FDA shortage list, compounding pharmacies lose the legal basis to prepare tirzepatide under Section 503A. They will have 60 days to stop production unless they obtain specific exemptions. The compounded market will likely shrink significantly in 2027.
Should I wait for Zepbound or start compounded tirzepatide now? If you have insurance coverage and Zepbound is available in your dose, start with brand Zepbound. If not, compounded tirzepatide offers comparable clinical outcomes at lower cost when sourced from a high-quality pharmacy. Waiting for supply to improve delays treatment without meaningful benefit.
How does Zepbound's "newness" affect its safety profile? Zepbound is 2.5 years post-approval, but tirzepatide has 10+ years of clinical trial data and 4 years of real-world use as Mounjaro. The safety profile is well-characterized. Rare adverse events (pancreatitis, gallbladder disease) were identified in early trials and have not increased in frequency with wider use.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- FDA Drug Shortages Database. Tirzepatide injection shortage entry. Updated April 2026.
- Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. May 2022.
- Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. November 2023.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
- Davies M et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
- Food and Drug Administration. Guidance for Industry: Compounding and the Food Drug and Cosmetic Act Section 503A. 2016.
- American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
- Centers for Medicare & Medicaid Services. Medicare Part D coverage determination for anti-obesity medications. 2024.
- National Institute for Health and Care Excellence. Tirzepatide for treating obesity: technology appraisal guidance. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Byetta, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →